References
Abdul-Ghani, M.A., Norton, L., DeFronzo, R.A. (2012). Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus. Current Diabetes Report , 12: 230-238.
Alexander, S.P., Fabbro, D., Kelly, E., Marrion, N.V., Peters, J.A., Faccenda, E., et al. (2017a). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes. British Journal Pharmacology , 174(Suppl 1): S272-S359.
Alexander, S.P., Peters, J.A., Kelly, E., Marrion, N.V., Faccenda, E., Harding, S.D., et al. (2017b). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Ligand-gated ion channels.British Journal Pharmacology , 174(Suppl 1): S130-S159.
Birkeland, K.I., Jørgensen, M.E., Carstensen, B., Persson, F., Gulseth, H.L., Thuresson, M., et al.(2017). Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. The Lancet Diabetes & Endocrinology, 5: 709-717.
Chao, E.C., Henry R.R. (2010). SGLT2 inhibition — a novel strategy for diabetes treatment. Nature Reviews Drug Discovery, 9: 551-559.
Cheng, X.D., Wei, M.G. (2014). Profiling the metabolism of astragaloside IV by ultra performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry.Molecules , 19: 18881-18896.
Chonlaket, P., Wongwan, T., Soodvilai, S. (2018). Liver X receptor activation inhibits SGLT2-mediated glucose transport in human renal proximal tubular cells. Experimental physiology , 103: 250-260.
Dow, C., Mancini, F., Rajaobelina, K., Boutron-Ruault, M.C., Balkau, B., Bonnet, F., et al. (2018). Diet and risk of diabetic retinopathy: a systematic review. European journal of epidemiology, 33: 141-156.
Filippas-Ntekouan, S., Filippatos, T.D., Elisaf, M.S. (2018). SGLT2 inhibitors: are they safe?Postgrad Med , 130: 72-82.
Gerstein, H.C., Miller, M.E., Byington, R.P., Goff, D.C., Bigger, J.T., Buse, J.B., et al.(2008). Effects of intensive glucose lowering in type 2 diabetes.The New England journal of medicine, 358: 2545-2559.
Guido, M.C., Marques, A.F., Tavares, E.R., Tavares de Melo, M.D., Salemi, V.M.C., Maranhao, R.C. (2017). The Effects of Diabetes Induction on the Rat Heart: Differences in Oxidative Stress, Inflammatory Cells, and Fibrosis between Subendocardial and Interstitial Myocardial Areas. Oxidative medicine and cellular longevity , 2017: 5343972.
Han, E., Jang, S.Y., Kim, G, Lee, Y.H., Choe, E.Y., Nam, C.M., et al. (2016). Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.Medicine , 95: e2786.
Harding, S.D., Sharman, J.L., Faccenda, E., Southan, C., Pawson, A.J., Ireland, S., et al.(2018). The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.Nucleic acids research, 46: D1091-D1106.
Hostalek, U., Gwilt, M., & Hildemann, S. (2015). Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs , 75: 1071-1094.
Ikonomidis, I., Pavlidis, G., Lambadiari, V., Kousathana, F., Triantafyllidi, H., Varoudi, M., et al. (2016). Improvement of arterial stiffness and LV myocardial deformation in patients with coronary artery disease and diabetes mellitus type 2 after 6-month treatment with metformin and agonists of GLP-1R. European Heart Journal , 37: 176-177.
Lam, K.S., Chow, C.C., Tan, K.C., Ma, R.C., Kong, A.P., Tong, P.C., et al. (2016). Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. Current Medical Research Opinion , 32: 1097-1108.
Liu, X., Wang, W., Song, G., Wei, X., Zeng, Y., Han, P., et al. (2017). Astragaloside IV ameliorates diabetic nephropathy by modulating the mitochondrial quality control network. PloS one , 12: e0182558.
Liu, Y., Liu, W., Li, J., Tang, S., Wang, M., Huang, W., et al. (2019). A polysaccharide extracted from Astragalus membranaceus residue improves cognitive dysfunction by altering gut microbiota in diabetic mice. Carbohydrate Polymers , 205: 500-512.
Lu, W.S., Li, S., Guo, W.W., Chen, L.L., Li, Y.S. (2015). Effects of Astragaloside IV on diabetic nephropathy in rats. Genetics and molecular research. Genetics Molecular Research , 14: 5427-5434.
Lu, Y.T., Ma, X.L., Xu, Y.H., Hu, J., Wang, F., Qin, W.Y., et al. (2018). A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells. Natural Product Bioprospect , 9: 13-21.
Monami, M., Dicembrini, I., Mannucci, E. (2017). Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Acta diabetologica , 54: 19-36.
Moucheraud, C., Lenz, C., Latkovic, M., Wirtz, V.J. (2019). The costs of diabetes treatment in low- and middle-income countries: a systematic review. BMJ global health , 4: e001258.
Naito, R., Miyauchi, K. (2017). Coronary Artery Disease and Type 2 Diabetes Mellitus Current Treatment Strategies and Future Perspective. International Heart Journal , 58: 475-480.
Nauck, M.A. (2014). Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.Drug design, development and therapy, 8: 1335-1380.
Navarro-Perez, J., Orozco-Beltran, D., Gil-Guillen, V., Pallares, V., Valls, F., Fernandez, A. et al. (2018). Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. BMC cardiovascular disorders , 18: 180.
Pandey, A., Chawla, S., Guchhait, P. (2015). Type-2 diabetes: Current understanding and future perspectives.IUBMB life, 67: 506-513.
Pernicova, I., Korbonits, M. (2014). Metformin—mode of action and clinical implications for diabetes and cancer. Nature Reviews Endocrinology, 10: 143.
Pop-Busui, R., Braffett, B.H., Zinman, B., Martin, C., White, N.H., Herman, W.H., et al. (2017). Cardiovascular Autonomic Neuropathy and Cardiovascular Outcomes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care , 40: 94-100.
Ran, R.X., Zhang, C.Z., Li, R.S., Chen, B.W., Zhang, W.H., Zhao, Z.Y., et al. (2016). Evaluation and Comparison of the Inhibition Effect of Astragaloside IV and Aglycone Cycloastragenol on Various UDP-Glucuronosyltransferase (UGT) Isoforms.Molecules, 21.
Reid, J., Rana, K., Niman, S., Sheikh-Ali, M., Lewis, T., Choksi, R.R., et al. (2020). Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention. American Journal of Cardiovascular Drug , 1-11.
Ren, C., Liu, W., Li, J., Cao, Y., Xu, J., Lu, P. (2019). Physical activity and risk of diabetic retinopathy: a systematic review and meta-analysis. Acta diabetologica , 56(1): 823-837.
Rieg, T., Vallon, V. (2018). Development of SGLT1 and SGLT2 inhibitors. Diabetologia , 61: 2079-2086.
Rives, M.L., Javitch, J.A., Wickenden, A.D. (2017). Potentiating SLC transporter activity: Emerging drug discovery opportunities. Biochemcal Pharmacology , 135: 1-11.
Rodbard, H.W., Blonde, L., Braithwaite, S.S., Brett, E.M., Cobin, R.H., Handelsman, Y., et al. (2007). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrinology Practice , 13(Suppl 1): 1-68.
Scheen, A.J. (2017). Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes. Expert review of clinical pharmacology, 10: 1303-1316.
Shan, G., Zhou, X.J., Xia, Y., Qian, H.J. (2016). Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting tubular epithelial-mesenchymal transition in vivo and in vitro. Experimental Therapeutic Medicine , 11:1611-1616.
Shyangdan, D.S., Uthman, O.A., Waugh, N. (2016). SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.BMJ open , 6: e009417.
Szabo, N.J. (2014). Dietary safety of cycloastragenol from Astragalus spp.: Subchronic toxicity and genotoxicity studies. Food Chemical Toxicology , 64:322-334.
Tang, F., Hao, Y., Zhang, X., Qin, J. (2017). Effect of echinacoside on kidney fibrosis by inhibition of TGF-beta1/Smads signaling pathway in the db/db mice model of diabetic nephropathy. Drug design, development and therapy, 11:2813-2826.
Tao, S., Li, L., Li, L., Liu, Y., Ren, Q., Shi, M., et al. (2019). Understanding the gut-kidney axis among biopsy-proven diabetic nephropathy, type 2 diabetes mellitus and healthy controls: an analysis of the gut microbiota composition.Acta diabetologica , 56: 581-592.
Vaduganathan, M., Butler, J. (2019). SGLT-2 inhibitors in heart failure: a new therapeutic avenue.Nature Medicine , 25: 1653-1654.
Vaidya, V., Gangan, N., Sheehan, J. (2015). Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review. Expert Review Pharmacoeconomics Outcomes, 15: 487-497.
Vivian, E.M. (2015). Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes. American journal of health-system pharmacy , 72: 361-372.
Wang, X.X., Levi, J., Luo, Y., Myakala, K., Herman-Edelstein, M., Qiu, L., et al. (2017). SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy. The Journal of biological chemistry , 292: 5335-5348.
Wang, Z.S., Xiong, F., Xie, X.H., Chen, D., Pan, J.H., Cheng, L. (2015). Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. BMC Nephrology ,16: 44.
Wood, I,S,, Trayhurn, P, (2003). Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. British Journal Nutrition , 89: 3-9.
Wright, E.M., Loo, D.D.F., Hirayama, B.A. (2011). Biology of Human Sodium Glucose Transporters.Physiological Review , 91: 733-794.
Xu, M.E., Xiao, S.Z., Sun, Y.H., Ou-Yang, Y., Zheng, X.X. (2006). Effects of astragaloside IV on pathogenesis of metabolic syndrome in vitro. Acta Pharmacol Sin,27: 229-236.
Yu, J., Zhang, Y., Sun, S., Shen, J., Qiu, J., Yin, X., et al. (2006). Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats.Canadian journal of physiology and pharmacology, 84:579-587.
Yue, S.J., Liu, J., Feng, W.W., Zhang, F.L., Chen, J.X., Xin, L.T., et al. (2017). System Pharmacology-Based Dissection of the Synergistic Mechanism of Huangqi and Huanglian for Diabetes Mellitus. Front Pharmacology, 8. 694.
Zhang, J., Wu, C., Gao, L., Du, G., Qin, X. (2020). Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Advanced Pharmacology , 87: 89-112.
Zhang, N., Wang, X.H., Mao, S.L., Zhao, F. (2011). Astragaloside IV improves metabolic syndrome and endothelium dysfunction in fructose-fed rats. Molecules , 16: 3896-3907.
Zhou, R.N, Song, Y.L., Ruan, J.Q., Wang, YT, Yan, R. (2012). Pharmacokinetic Evidence on the Contribution of Intestinal Bacterial Conversion to Beneficial Effects of Astragaloside IV, a Marker Compound of Astragali Radix, in Traditional Oral Use of the Herb. Drug Metabolism Pharmacokonet , 27:586-597.
Zhou, X., Sun, X., Gong, X., Yang, Y., Chen, C., Shan, G., et al. (2017). Astragaloside IV from Astragalus membranaceus ameliorates renal interstitial fibrosis by inhibiting inflammation via TLR4/NF-small ka, CyrillicB in vivo and in vitro. International Immunopharmacolology, 42: 18-24.